Cidara Therapeutics, which is developing novel therapies for fungal infections, filed on Friday with the SEC to raise up to $69 million in an initial public offering.
Last year's antifungal biotech SCYNEXIS (SCYX) trades at about its offer price.
The San Diego, CA-based company, which was founded in 2012, plans to list on the NASDAQ under the symbol CDTX. Cidara Therapeutics initially filed confidentially on February 4, 2015. Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
